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Background. Antibody to complement C1q (Anti-C1q 
Antibody) can be found in Systemic Lupus 
Erythematosus (SLE) patients. Complement C1q plays a 
role in the clearance of apoptotic cells and immune 
complexes. Anti-C1q causes complement C1q become 
inactive so that the clearance decreases, which induces 
self antigen and inflammatory response. Many tissue 
inflammation are associated with disease activity and 
lupus manifestations. The aim of this study is to find out 
the correlation of anti-C1q level with disease activity, so 
that anti-C1q can be used as an objective indicator of 
inflammation along with SELENA-SLEDAI.  
Method. This is an analytic descriptive study with 
cross sectional design. Anti-C1q antibody levels were 
measured in 52 SLE patients who are hospitalized or 
treated routinely in outpatient clinic of Rheumatology 
Dr.Hasan Sadikin Hospital Bandung Indonesia from 
October to December 2015. 
Result. Most of the study subjects were women 
(94%), with a median age of 33 years. There were 13 
new patients (25%), and the rest 42 patients were 
treated routinely. The median SELENA-SLEDAI was 
6 (0-32). Subject were divided into no activity 
(11.5%), low disease activity (34.6%), medium 
disease activity (25%) high disease activity (15.4%) 
and very high disease activity (13.5%). Median anti-
C1q level was 3.92 U/mL (range 0.6-100.2 U/mL). 
Anti-C1q antibody levels were positively correlated 
with SLE disease activity based on SELENA-SLEDAI 
scores (r=+0.304; p=0.014) Conclusion. Anti-C1q 
antibody levels has mild correlated with lupus 
disease activity based on SELENA-SLEDAI score  




Systemic lupus erythematosus (SLE) is a prototypic 
systemic autoimmune disease characterized by 
heterogeneous multisystem involvement. Clinical 
features, course of disease and the prognosis can be 
quite variable.1 Lupus primarily affects women of 
childbearing years.2 Many research highlight the 
increased mortality rate in SLE patients compared 
with the general population.3,4 Immune system in SLE 
patient characterized by lymphocytes B cell 
hyperactivity and autoantibody production.1 One of 
the pathogenesis of SLE is a disorder of the 
 
 
clearance of apoptotic cells.1,4 The complement 
system plays a significant role in facilitating the 
clearance of apoptotic cells and immune complexes 
and prevent the accumulation of immune complex 
organ systems.1,5,6,7 Complement C1q is a component 
of the initiation of the classical pathway (what kind of 
the pathway?) and plays an important role in the 
complement system as a whole.8  
Antibodies to complement C1q (Anti-Clq 
Antibody) can be found in patients with SLE due to 
chronic activation of the complement system.9 
Anti-C1q antibody disrupts the clearance of 
immune complexes and cell apoptosis. Immune 
complexes becomes bulky and not easily soluble, 
The immune complex will be the source of 
inflammation amplification (disease activity). 
Prolonged inflammation would cause irreversible 
tissue damage (disease damage).1  
Disease activity which very fluctuated in lupus 
patients requires objective monitoring clinical 
parameters.1 Castrejon et al. reported that a 
parameter that is widely used in the world and is 
recommended for use in future studies is the Safety 
of Estrogens in Lupus Erythematosus National 
Assessment Systemic Lupus Erythematosus 
Disease Activity Index (SELENA-SLEDAI) and 
SLEDAI-2K.10  
Studies of anti-C1q antibodies in various 
countries, found variation in research results. Some 
studies found a link between levels of anti-C1q 
antibodies with disease activity, 11-16 while other 
studies do not found the relationship.17-19 One of the 
causes of such diversity is, there is a difference 
between research race with one another. This study is 
the first in Dr. Hasan Sadikin Hospital Bandung 
Indonesia and all of the subjects are Asiatic race. The 
results of this study is expected to add the role of anti-
C1q antibodies in patients with lupus.  
The aims of this study is to determine the 
correlation of anti-C1q antibody levels with disease 
activity score based on the SELENA-SLEDAI in 
patients with SLE. 
 
Methods 
This research is descriptive analytic and a cross-
sectional design. Targeted population are SLE 
patients who are diagnosed based on revised criteria 
of SLE from American College of Rheumatology 
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(ACR). Sampling was performed consecutively within a 
certain time, fulfil=fufill? the minimum sample of 52 to the 
power of study. The inclusion criteria of research are women 
and men aged over 14 years (not over 18 years?) who were 
diagnosed SLE, outpatients and inpatients, and had signed 
informed consent. Exclusion criteria included pregnant 
patients, suffered from hepatitis B or C, patients with severe 
medical conditions or psychiatric disorder that causes 
uncooperative.  
All the subjects who were eligible were evaluated using 
SELENA-SLEDAI score, then were performed venous blood 
sampling, included routine hematology test, anti-C1q 
antibody level, levels of complement C3 and levels of anti-
dsDNA and urine test. Anti-C1q levels were measured using 
micro ELISA.  
Characteristics of research subjects are presented in tabular 
form,(table no.) correlation between anti-C1q antibodies level 
with lupus disease activity was calculated by Spearman 
Correlation Test. Data were analyzed using wessa program.  
(?) All statistical tests were considered significant if p value  
<0.05. Ethical clearance was obtained from the Research 




The study sampling was conducted from October to 
December 2015 and obtained 52 subjects. 
 
Table 1. Characteristics of Subjects (n=52)   
Variable Total  
 
 
Table 1 shows the baseline characteristics of subjects. Most of the 
subjects were woman (94%), with an mean age at 33 + 10 
years(please use the usual word). Most of the subjects were 
outpatient. Disease activity based on the SELENA-SLEDAI score 
had a median of 6. The therapy(better use treatment) most widely 
used by subjects is methylprednisolone (100%). Other 
therapy(better use treatment) were chloroquine, azathioprine, 



















Figure 1. History of organ involvement from 52 consecutive 
patients with active systemic lupus erythematosus (SLE) was 
mucocutaneous involvement as much as 84.6%, 78.8% 
musculoskeletal and 53.8% renal involvement. Organ involvement 
at the time of research is 42.3% renal involvement, 19.2% 
mucocutaneous and 15.4% musculoskeletal 
 
Sex (n, %)  
- Male  
- Female  
Age at the time of research (mean in years)  
Age at diagnosed (mean years)  
SLE duration (years)  
Types of Treatment (n, %)  
- Outpatients  
- Inpatients  
SELENA SLEDAI  
- Without activity (Score 0)  
- Mild activity (Score 1–5)  
- Moderate activity (6–10)  
- High activity (11–19)  
- Very high activity 
(>20) Laboratorium 
- Hemoglobin (g/dL)  
- Leukosit (/mm3)  
- Platelet (/mm3)  
- C3 (mg/dL)  
- Anti-dsDNA (IU/mL) 
Medication (n, %) 
- methylprednisolone  
- chloroquine  
- azathioprine  
- cyclosporine  
- cyclophosphamide  
- Methorexate  
- Mycophenolate mofetil  
 
3 (5.8)  





42 (80.8)  
10 (19.2)  
6 (0-32)  
6 (11.5)  
18 (34.6)  
13 (25)  









52 (100)  
23 (44)  
10 (19)  
1 (2)  
6 (11)  
2 (4)  
0 (0) 
 
The most dominant history of organ involvement was 
mucocutaneous involvement as much as 84.6%, 78.8% 
musculoskeletal and 53.8% renal involvement. The Most 
organ involvement at the time of research is (was) 42.3% renal 
involvement, 19.2% mucocutaneous and 15.4% 





















Figure 2. Correlations between anti-C1q antibody titers and 
SELENA-SLEDAI score, as measured in 52 consecutive 
patient with active SLE. For comparison, significant positive 
correlation (p = 0.014) were observed. 
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This study showed a mild correlation between Anti-C1q 
antibody levels and SLE disease activity based on SELENA-
SLEDAI score. (Figure 2) 
 
Table 2. Differences in levels of anti-C1q antibodies in 




Antibodi anti-C1q levels 
  
Median P value    
Mucocutaneus 
10 3,83 0,736 - Yes 
- No 42 3,92  
Musculoskeletal 
8 3,63 0,525 - Yes 
- No 44 3,93  
Renal  
22 10,05 0,004* - Yes 
- No 30 3,49  
Hematologic 
6 3,84 0,376 - Yes 
- No 46 3,92  
NPSLE  
3 3.5 0,384 - Yes 
- No 49 3,92  
 
Table 2. showed that median of anti-C1q antibody in the 
group of SLE with renal involvement (10,05 U / mL) was 
higher than the group of SLE without renal involvement (3,49 
U / mL) and the difference was statistically significant 
(p<0.05), while mucocutaneous involvement, 
musculoskeletal involvement, haematological involvement 
and NPSLE are not statistically significant. 
 
Discussion 
This study found a (mild) positive correlation between levels 
of anti-C1q antibodies with lupus disease activity based on the 
SELENA-SLEDAI score (r=+0.304, p<0.05). Previous 
studies have shown that anti-C1q antibody levels in lupus 
patients correlates with disease activity, the strength of the 
correlation is varies from mild to strong correlation. Siegert et 
al. conducted cohort research for three years follow up and 
found serum anti-C1q were significantly but weak correlated 
with the SLEDAI score (r=+0,18; p<0.01)20, in contrast with 
research conducted by Cai et al. in China, found a strong 
correlation between the levels of anti-C1q antibodies with 
disease activity with SLEDAI score (r=+0.792, p<0.001).21 
Katsumata et al. in Japan, concluded that the anti-C1q 
antibody levels were correlated with SLEDAI score 2K (r= 
+0.34, p<0.0001).16 Mahayadin et al. in Malaysia conducted a 
cross-sectional study in 2014 with 95 patients with SLE, in 
which the research subjects are dominated by the Malays 
(95%). That study concluded that a strong correlation between 
the levels of anti-C1q antibodies with disease activity with 
SLEDAI scoring system (r=+0.559, p<0.001).22  
This study found serum anti-C1q differences between 
subjects with renal involvement and without renal 
involvement, whereas the involvement of mucocutaneous, 
musculoskeletal, hematologic and NPSLE are no statistically 
significant differences. It is also stated by Siegert et al. who 
Original Article 
 
comparing the levels of anti-C1q at various organ involvement, 
found differences in levels of anti-C1q patients with renal 
involvement but no difference in other organ involvement.20 Mok 
et al. measuring the levels of autoantibodies in patients with SLE, 
it was concluded that the anti-C1q antibodies specific for kidney 
involvement when compared with other antibodies.14 Akhter et al. 
stated that anti-C1q antibodies are superior when compared to 
(the) other markers such as anti-dsDNA to detect the presence of 
renal flares.13  
Differences in correlation (of the) anti-C1q antibody levels 
against global lupus disease activity or a variety of organ 
involvement in the various countries, likely due to their genetic 
diversity and differences in research methodology. The literature 
explains that the pathogenesis of SLE is closely related to genetic 
factors. In recent years Genome wide association study (GWAS) 
shows that there are more than a hundred genes involved in the 
pathogenesis of SLE, and each of these genes have effects that are 
moderate. Additional evidence shows that there are differences in 
the genes involved in a particular ethnic. For example, the gene 
that regulates FC Gamma Reseptor (FCGR) has long been 
associated with the pathogenesis of SLE in Asia. Until now 
FCGR2A, FCGR2B and FCGR3A polymorphism has been 
associated with SLE in Asia.23 Early research on the matter 
reported by Salmon et al. Which(was) found that differences in 
FCGR3A allele involved in the pathogenesis of SLE in Korea.24, 
when(which) associated with anti-C1q antibodies, Orbai et al. 
stated that anti-C1q antibody is(was?) more common in Asian 
ethnic (40.5%) compared with Caucasian ethnic (27.6%) and 
African (21.7%) although the difference was not significant.25 
Pradhan et al. in India mentioned that the secretion of anti-C1q 
antibodies were related to genetic polymorphisms of FCGR2A 
receptors. There are two alleles that encode FCGR2A ie H131 and 
R131. FC Gamma 2A receptor with H131 allele have a good 
affinity towards IgG2, while FC Gamma 2A receptor with R131 
allele have a weak affinity towards IgG2. Pradhan et al. found that 
patients with anti-C1q antibody positive, 71% had R131/H131 
genotype, 22.6% had R131/R131 genotype and 6.4% had 
H131/H131 genotype.26 In this study, the research subject is 
dominated by ethnic Sundanese, where, according to Kroeber AL, 
Sundanese belong to the Mongoloid Malayan similar ethnic 
Malays in a study conducted by Mahayadin et al. in Malaysia.22, 
Malayan Mongoloid ethnic still allied with the Asiatic Mongoloid 
such as Chinese and Japanese.27 This may explain why the 
correlation of research in Europe is different from research in 
Asia, ethnic differences are significant, as previously described, 
while the difference in strength of the correlation between ethnic 
Asiatics, such as in Malaysia, China, Japan and Indonesia needs 
to do further research as has been done by Pradhan et al. 
 
Limitation of this study is, the age of the study subjects was 
not uniform and as much as 75% of patients are outpatients where 
the study subjects have received immunosuppressive therapy. 
Some studies reports that anti-C1q antibody levels decreased after 
the administration of immunosuppressive drugs. 
Immunosuppressive drugs have a suppressive effect on T cells 
and B cells. This suppression causes a decrease in the immune 
response and decreased production of autoantibodies 
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in patients with SLE, including decreased 
production of anti-C1q autoantibodies. Beside 
that, the method of this study was cross-sectional 
so that the strength of the relationship of variables 
to be lower when compared to a cohort study. 
 
Conclusion 
The results of this study shows a mild positive 
correlation and statistically significant between anti-
C1q antibodies levels with disease activity in 
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